Inventor · disambiguated record
Jedd D. Wolchok
Also filed as: WOLCHOK JEDD · WOLCHOK JEDD D · WOLCHOK JEDD DAVID
36 granted patents·32 pending applications·122 citations·filing 2001–2025
97Inventor score
Files withMEMORIAL SLOAN KETTERING CANCER CENTER38AGENUS INC18ICAHN SCHOOL MED MOUNT SINAI6SLOAN KETTERING INST CANCER3ALPHAVAX INC1
Top patents by PatentIndex Score
68 records- 0197US10912831B1Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted Feb 9, 2021·6 cites·26 claims
- 0296US11638755B2Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted May 2, 2023·4 cites·20 claims
- 0396US10736962B2Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumorsMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2017·Granted Aug 11, 2020·15 cites·22 claims
- 0495US12036279B2Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumorsMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2022·Granted Jul 16, 2024·2 cites·8 claims
- 0595US11986503B2Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapyMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2022·Granted May 21, 2024·2 cites·14 claims
- 0694US11285209B2Recombinant MVA or MVAΔE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumorsMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2020·Granted Mar 29, 2022·3 cites·10 claims
- 0794US11253560B2Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumorsMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2020·Granted Feb 22, 2022·3 cites·19 claims
- 0894US10639366B2Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumorsMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2016·Granted May 5, 2020·10 cites·16 claims
- 0994US10548930B2Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumorsMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2016·Granted Feb 4, 2020·15 cites·18 claims
- 1094US10144779B2Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2016·Granted Dec 4, 2018·12 cites·92 claims
- 1193US11541087B2Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapyMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2020·Granted Jan 3, 2023·2 cites·12 claims
- 1293US11013802B2Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2017·Granted May 25, 2021·5 cites·21 claims
- 1393US10512662B2Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapyMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2017·Granted Dec 24, 2019·6 cites·20 claims
- 1492US11267889B2Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted Mar 8, 2022·2 cites·26 claims
- 1592US10479833B2Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2018·Granted Nov 19, 2019·8 cites·34 claims
- 1689US11345755B2Anti-PD-1 antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted May 31, 2022·2 cites·25 claims
- 1788US10800849B2Anti-GITR antibodies and methods of use thereofAGENUS INC·Filed 2018·Granted Oct 13, 2020·2 cites·26 claims
- 1888US10251922B2Newcastle disease viruses and uses thereofICAHN SCHOOL MED MOUNT SINAI·Filed 2017·Granted Apr 9, 2019·5 cites·20 claims
- 1987US10765711B2Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human FLT3L or GM-CSF for cancer immunotherapyMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2019·Granted Sep 8, 2020·2 cites·19 claims
- 2087US10577426B2Anti-GITR antibodies and methods of use thereofAGENUS INC·Filed 2018·Granted Mar 3, 2020·3 cites·21 claims
- 2186US10323091B2Anti-PD-1 antibodies and methods of use thereofAGENUS INC·Filed 2016·Granted Jun 18, 2019·5 cites·94 claims
- 2285US12246066B2Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2023·Granted Mar 11, 2025·0 cites·19 claims
- 2384US11993653B2Antibodies and methods of use thereofAGENUS INC·Filed 2019·Granted May 28, 2024·2 cites·19 claims
- 2484US2025177518A1Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumorsMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2024·Application pending·0 cites
- 2582US2023039577A1Anti-gitr antibodies and methods of use thereofAGENUS INC·Filed 2022·Application pending·0 cites
- 2681US12042534B2Newcastle disease viruses and uses thereofICAHN SCHOOL MED MOUNT SINAI·Filed 2018·Granted Jul 23, 2024·1 cites·9 claims
- 2779US12492257B2Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2022·Granted Dec 9, 2025·0 cites·20 claims
- 2879US12397029B2Use of MVA or MVADELTAE3L as immunotherapeutic agents against solid tumorsMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2022·Granted Aug 26, 2025·0 cites·13 claims
- 2976US2022372149A1Anti-pd-1 antibodies and methods of use thereofAGENUS INC·Filed 2022·Application pending·0 cites
- 3075US11884939B2Vaccinia virus mutants useful for cancer immunotherapyMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2021·Granted Jan 30, 2024·0 cites·16 claims
- 3175US2024239910A1Bi-specific activators for tumor therapyMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2023·Application pending·0 cites
- 3275US2025360209A1Anti-ctla-4 antibodies and methods of use thereofAGENUS INC·Filed 2025·Application pending·0 cites
- 3375US2025127879A1Newcastle disease viruses and uses thereofICAHN SCHOOL MED MOUNT SINAI·Filed 2024·Application pending·0 cites
- 3473US11401335B2Anti-GITR antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted Aug 2, 2022·0 cites·16 claims
- 3572US2024408251A1Compositions and methods for targeted particle penetration, distribution, and response in malignant brain tumorsMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2023·Application pending·0 cites
- 3670US12252702B2Recombinant poxviruses for cancer immunotherapyMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2019·Granted Mar 18, 2025·0 cites·24 claims
- 3769US2025026855A1Antigen-binding proteins targeting melanoma differentiation antigens and uses thereofMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2023·Application pending·0 cites
- 3868US7556805B2Compositions for treatment of melanoma and method of using sameSLOAN KETTERING INSTSTUTE FOR·Filed 2001·Granted Jul 7, 2009·4 cites·10 claims
- 3967US12331359B2Neoantigens and uses thereof for treating cancerICAHN SCHOOL MED MOUNT SINAI·Filed 2018·Granted Jun 17, 2025·1 cites·21 claims
- 4067US2024189426A1Chimeric receptors targeting muc16 and uses thereofMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2024·Application pending·0 cites
- 4166US10450373B2Anti-PD-1 antibodies and methods of use thereofAGENUS INC·Filed 2019·Granted Oct 22, 2019·0 cites·30 claims
- 4266US2024042031A1Antigen recognizing receptors targeting gd3 ganglioside and uses thereofMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2023·Application pending·0 cites
- 4365US11242509B2Vaccinia virus mutants useful for cancer immunotherapyMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2018·Granted Feb 8, 2022·0 cites·20 claims
- 4463US11426460B2Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumorsMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2020·Granted Aug 30, 2022·0 cites·20 claims
- 4563US2021369795A1Methods and compositions for identifying and treating subjects at risk for checkpoint blockade therapy associated colitisMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2021·Application pending·0 cites
- 4663US2020113984A1Alphavirus Replicon Particles Expressing TRP2ALPHAVAX INC·Filed 2019·Application pending·0 cites
- 4762US2025179524A1Recombinant poxviruses for cancer immunotherapyMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2025·Application pending·0 cites
- 4860US2014271677A1Newcastle Disease Viruses and Uses ThereofSLOAN KETTERING INST CANCER·Filed 2014·Application pending·0 cites
- 4960US2016015760A1Newcastle disease viruses and uses thereofICAHN SCHOOL MED MOUNT SINAI·Filed 2014·Application pending·0 cites
- 5059US2024109973A1Cd40 binding molecules and uses thereofMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2021·Application pending·0 cites
Showing the top 50 of 68 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →